Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

November 26, 2020

Study Completion Date

August 8, 2024

Conditions
Chronic Hepatitis Delta
Interventions
DRUG

Bulevirtide

Administered via SC injections

Trial Locations (19)

10016

New York University School of Medicine, an administrative unit of New York University, an education corporation, New York

10021

Cornell University Well Madical College, New York

Unknown

Universitätsklinikum Essen (AoR), Klinik für Gastroenterologie und Hepatologie, Essen

Universitätsklinikum Frankfurt Medizinische Klinik 1, Frankfurt am Main

Universitätsklinikum Hamburg-Eppendorf, Hamburg

Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hanover

Heidelberg University Hospital, Departament of Gastroenterology, Infectious Diseases, Intoxication, Heidelberg

Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan

Università di Modena e Reggio Emilia- Ospedale Civile S., Modena

U.O. Epatologia - Azienda Ospedaliero Universitaria Pisana, Pisa

"State Budgetary Educational Institution of Higher Professional Education South Ural State Medical University of the Ministry of Healthcare of the Russian Federation", Chelyabinsk

Specialized clinical Infectious diseases Hospital, Krasnodar

"Federal Budget Institution of Science Central Research Institute of Epidemiology of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance", Moscow

Federal State Budgetary Institution National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow

"LLCClinic of Modern Medicine", Moscow

Moscow Regional Scientific and Research Clinical Institute, Moscow

"LLC Medical Company Hepatolog", Samara

Stavropol Regional Hospital, Stavropol

Karolinska University Hospital Huddinge, Dept of Infectious Diseases, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT03852719 - Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) | Biotech Hunter | Biotech Hunter